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Introduction: The purpose of this analysis was to determine if abnormal diffusing capacity
of the lung for carbon monoxide (DLco) identified a group of subjects with significantly
different characteristics than those with normal lung function or airflow obstruction alone.
Methods: Participants were a random sample of adults aged 45–70 years. They completed
a detailed respiratory questionnaire, spirometry, methacholine challenge and measure-
ment of single breath DLco. Subjects were categorized into one of three groups: airflow
obstruction only, reduced DLco only, or both airflow obstruction and reduced DLco.
Results: Individuals with airflow obstruction and reduced DLco in combination reported
more symptoms than those with either condition alone. In subjects with a combination of
both airflow obstruction and reduced DLco, a significantly higher proportion reported use
of medication and laboratory tests. Current smoking was significantly associated with a
reduced DLco alone and in combination with airflow obstruction, however, the association
was stronger in those with DLco and airflow obstruction. Bronchial hyperreactivity (BHR)
was found to be a risk factor while atopy was associated with a reduced risk of DLco and
airflow obstruction.
Conclusions: Reduced DLco plus airflow obstruction together identifies a group of
individuals with significantly more symptoms and worse lung function. Current cigarette
smoking, early life serious respiratory infection and BHR were strongly associated with
reduced DLco in combination with airflow obstruction.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The
l.: +61 3 8344 0713; fax: +61 3 9349 5815.
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Reduced diffusing capacity and airflow obstruction 1731Introduction
Chronic obstructive pulmonary disease (COPD) is a major
contributor to the burden of disease internationally. The
prevalence is continuing to increase and it is widely under-
diagnosed particularly in the primary care setting.1 Early
diagnosis can lead to better treatment/intervention options
that may modify the natural history of the disease and
reduce the overall burden of COPD to the general commu-
nity. In order to accurately assess the burden of disease and
identify high-risk groups, risk factors for the development
of COPD need to be determined using epidemiological
approaches. This requires a consistent definition of COPD
which has been lacking in the literature to date.
All the currently published guidelines have highlighted
the importance of physiologically defining COPD using
spirometry. The ratio of forced expiratory volume in 1 s
(FEV1) to forced vital capacity (FVC) is accepted as an
indicator of airflow obstruction and percent predicted FEV1
is used to grade severity. However, the prevalence of disease
can vary with the cut-off level used to define airflow
obstruction, which varies between the GOLD,2 BTS,3 ERS,4
ATS,5 Australian COPD-X6 guidelines and clinical criteria.
High-resolution computed tomography (HRCT) of the chest is
the most accurate imaging technique to detect pulmonary
emphysema in vivo7 and is considered the gold standard in
defining emphysema clinically.8 However, HRCT involves a
substantial dose of ionising radiation and is prohibitively
expensive for large epidemiological studies. Diffusing capacity
of the lung for carbon monoxide (DLco) is a good predictor of
emphysema when correlated with postmortem morphological
measurements9 and correlates well with the extent of
emphysema on HRCT.10 Measurement of DLco is a more feasible
and acceptable alternative to HRCT for epidemiological studies
and has already been used for occupational monitoring.11
Spirometry is considered the gold standard for detecting
and quantifying airflow obstruction in the general population.
However, several studies have failed to find a strong
association between the parenchymal destruction seen in
emphysema and airflow obstruction as measured by FEV1.
12–14
This indicates that definitions that rely on measurement of
FEV1 alone may miss some cases of COPD. Including a
measurement of DLco may be one way to detect early cases
of emphysema that otherwise would go undetected.
Comparison of the different definitions for airflow obstruction
for defining COPD for epidemiological studies have been
evaluated previously.15 Celli et al. found the different defini-
tions of obstruction produced prevalence estimates that varied
by as much as 200%. However, an epidemiological definition
incorporating a measurement of DLco has not previously been
widely used or evaluated. The purpose of this analysis was to
determine if abnormal DLco identified a group of subjects with
significantly different clinical characteristics than those with
normal lung function or airflow obstruction alone.
Methods
Participants
Recruitment and lung function testing have been described
in detail elsewhere.16,18 Briefly, 7005 adults aged between45 and 70 years were randomly selected from the electoral
rolls for three inner south eastern Melbourne electorates. A
screening questionnaire was completed by 4923 subjects
(70% response rate) and 2900 of these participants were
invited to attend our lung function laboratory. A total of
1232 Caucasian subjects (42% response rate) attended. The
study was approved by the Ethics Committees at Monash
University and The Alfred Hospital, Melbourne, Australia. All
participants gave written informed consent.Lung function testing
Spirometry and single breath carbon monoxide diffusing
capacity (DLco) were performed according to the American
Thoracic Society (ATS) criteria.17,18 Predicted values for
FEV1, FVC and FEF2575 were calculated from age, height
and gender using equations by Gore et al.,19 and for FEV1/
FVC%, DLco and DLco/VA using the equations by Quanjer et
al.20 Methacholine (MCh) (USP Methapharm Inc., Brantford,
Ontario, Canada) was delivered by a Mefar 3B dosimeter
(Mefar, Bovezzi, Italy) until FEV1 fell by 20% from the initial
value (PD20) or up to a cumulative dose of 2mg.Definitions
Morning cough was defined as a positive response to: ‘‘Do you
usually cough first thing in the morning in the winter’’? Chronic
cough was defined as a positive response to: ‘‘Do you cough like
this on most days for as much as 3 months each year’’? Morning
sputum was defined as a positive response to: ‘‘Do you usually
bring up phlegm from your chest first thing in the morning in the
winter’’? Chronic bronchitis was defined as a positive response
to: ‘‘Have you brought up phlegm on most days for as much as 3
months of a year for at least 2 successive years’’? Shortness of
Breath-grade 2 (SOB grade 2) was defined as a positive response
to: ‘‘Are you troubled by shortness of breath when hurrying on
level ground or walking up a slight hill’’? SOB Grade 3 was
defined as a positive response to: ‘‘Do you have to stop for
breath when walking at your own pace on level ground’’?
Wheeze was defined as a positive response to: ‘‘Have you had
wheezing or whistling in your chest at any time in the last 12
months’’? Exertional SOB was defined as a positive response to:
‘‘Have you been short of breath following strenuous activity in
the last 12 months’’? Serious early respiratory tract infection
(serious early RTI) was defined by a positive response to the
question ‘‘Did you have a serious respiratory infection before
the age of 5 years’’? (including croup requiring hospitalisation,
bronchiolitis, wheezy bronchitis, pneumonia, diphtheria, tu-
berculosis, whooping cough)’’. Current asthma for this analysis
was defined by a positive response to the question ‘Have you
had an attack of asthma in the last 12 months’?
Airflow obstruction was defined as FEV1/FVC ratioolower
limit of normal (LLN).21 Reduced diffusing capacity was
defined as a DLcooLLN.22 The LLN was calculated as the
value falling 1.64 standard deviations (SD) below the
predicted mean. Bronchial hyperresponsiveness (BHR) was
defined as a provocative dose of methacholine causing a 20%
fall in FEV1 (PD20) less than 2mg. Bronchial reactivity was
also expressed as the dose response slope (DRS) ¼ (percentage
change in FEV1+3.5)/MCh dose.
23,24 Pack years were calculated
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20 and multiplied by the number of years smoked.
Subject groupings
Subjects were categorized into one of four groups; (1)
normal lung function (FEV1/FVC X LLN, DLco X LLN), (2)
reduced diffusing capacity only (DLcooLLN) (3) airflow
obstruction only (FEV1/FVCoLLN), (4) both airflow obstruc-
tion and reduced diffusing capacity (Both FEV1/FVC and
DLcooLLN). Body mass index (BMI) was calculated as the
ratio of body weight (kg) to height squared (m2). Height and
weight were measured in the standing position in subjects
wearing clothes, but without shoes.
Statistical analysis
The statistical package STATA (version 6.0; STATA Corpora-
tion, Texas) was used for all analyses. Intra-class (within
individual) correlation was used to assess agreement
between duplicate measurements of DLco, alveolar volume
(VA), and inspiratory vital capacity (VCinsp). All the variables
listed in Table 2 were considered as possible covariates.
In the univariate analysis, the associations between
variables listed in Table 2 and the four categories were
analysed by either a w2-test or an exact test for binary
variables or ANOVA for continuous variables. Multinomial
(polytomous) logistic regression was used to identify those risk
factors that were independently associated with disease risk.
Group 1 normal lung function (FEV1/FVCXLLN, DLcoXLLN)
was used as the base category. Age and gender were fitted to
all models and subjects who reported an asthma attack in the
last 12 months were excluded from the analysis.
Results
Characteristics of the study population
Table 1 presents lung function characteristics of the four
groups. As would be expected those with a combination ofTable 1 Lung function characteristics of the study population
Lung function Normal DLcooLL
Mean (7SD) n ¼ 807 n ¼ 145
FEV1 (L) 3.2370.77 3.5870
FEV1% Predicted 109.8714.1 99.071
FVC (L) 4.1170.97 4.6170
FVC % predicted 111.0713.6 100.371
FEV1/FVC % 78.674.27 78.074
FEF2575 (L/s) 3.0471.01 3.2771
FEF2575% Predicted 2.8370.53 3.3270
DLco ml/min/mmHg 23.675.59 22.473
DLco % Predicted 101.1712.4 77.978
DLco/VA ml/min/mmHg/L 4.1870.61 3.6370
DLco/VA % predicted 73.2711.6 67.379
Bronchial reactivity (log
dose response slope)
1.7471.10 n ¼ 732 1.3470both reduced diffusing capacity and airflow obstruction have
a greater degree of obstruction and diffusing impairment
than those with a single lung function defect. Bronchial
reactivity (log DRS) was also highest in the pure airflow
obstruction group.
Selected characteristics by disease group are presented in
Table 2. There was a small but significant difference in mean
age and proportion of males between the groups. Those with
both a reduced diffusing capacity and airflow obstruction
were significantly more likely to have ever smoked and be
current smokers.
Those with pure airflow obstruction or in combination
with reduced diffusing capacity were significantly more
likely to be using inhaled steroids and bronchodilator
medication. The mean BMI in all groups classified most
subjects as overweight, with the exception of those with
both a reduced diffusing capacity and airflow obstruction
where the mean BMI was at the high end of the normal
range.
The proportion of subjects who were atopic was sig-
nificantly higher among those without reduced diffusing
capacity. BHR was present in nearly half of subjects with
both airflow obstruction and reduced DLco, and over half of
those with airflow obstruction alone. In those with reduced
DLco however BHR was not very common. A significantly
greater proportion of subjects with both airflow obstruction
and reduced DLco reported a serious respiratory infection
before the age of 5 years. Significantly more subjects with a
combination of reduced diffusing capacity and airflow
obstruction had a paternal history of COPD and were
retired. However, there was no difference between groups
for occupational exposures to vapours, gases, dusts, or
fumes.Comparison of respiratory symptoms between
groups
Individuals with a combination of a reduced diffusing
capacity and airflow obstruction reported significantly more
wheeze, morning and chronic cough, morning and chronic
phlegm, Grade 2 and 3 SOB than other groups (Fig. 1).divided by disease group.
N only FEV1/FVCoLLN only Both
n ¼ 204 n ¼ 66
.74 2.7570.82 2.6870.92
5.2 91.1717.4 77.3719.8
.92 4.1571.12 4.3771.23
5.0 108.8716.3 99.5717.6
.18 65.675.39 59.4710.6
.02 1.5570.63 1.3270.66
.43 2.8670.59 3.0570.48
.91 24.176.63 20.175.43
.04 100.0713.3 72.9712.4
.50 4.0570.64 3.2070.62
.44 71.5712.6 59.9712.4
.76 n ¼ 123 3.5571.86 n ¼ 166 3.0871.95 n ¼ 41
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Table 2 Characteristics of the study population by group.
Symptom/history Normal DLcooLLN only FEV1/FVCoLLN only Both P*
n ¼ 807 n ¼ 145 n ¼ 204 n ¼ 66
Age years (mean7SD) 57.6477.35 56.977.25 57.978.03 60.877.08 0.005z
Sex (male) 347 (42.5) 138 (95.2) 97 (47.6) 55 (83.3) 0.0001
Ever smoker n (%) 371 (45.4) 95 (65.5) 97 (47.6) 52 (78.8) 0.0001
Current Smoker n (%) 81 (9.9) 41 (28.3) 25 (12.3) 26 (39.4) 0.0001
Pack years
n ¼ 364 n ¼ 94 n ¼ 97 n ¼ 52
Ever smoker (Median, IQR) 11 (4.4, 26) 21 (8, 42) 17 (6.3, 33) 34 (19, 46) 0.0001yy
n ¼ 78 n ¼ 41 n ¼ 25 n ¼ 26
Current smoker (Median, IQR) 15 (4.6, 33) 29 (11, 46) 30 (19, 43) 36 (20, 45) 0.0005yy
n ¼ 810 n ¼ 145 n ¼ 204 n ¼ 66
BMI kg/m2 (mean7SD) 27.574.47 27.873.79 27.075.37 25.973.81 0.02z
Treatment
Inhaled steroids n (%) 39 (4.8) 1 (0.7) 46 (22.6) 13 (19.7) 0.0001
Inhaled bronchodilators n (%) 83 (10.2) 9 (6.2) 74 (36.3) 21 (31.8) 0.0001
Asthma attack n (%) 61 (7.5) 5 (3.5) 64 (31.4) 12 (18.2) 0.0001
Atopy n (%) 413 (51.0) 74 (51.0) 126 (61.8) 30 (45.5) 0.03
BHR n (%) 103 (13.9) 7 (5.6) 104 (53.6) 26 (42.6) 0.0001
Serious RI before 5 yrs n (%) 184 (22.7) 34 (23.5) 56 (27.7) 29 (43.9) 0.001
Employment status
Employed n (%) 523 (64.0) 112 (77.2) 133 (65.2) 39 (59.1)
Not employed n (%) 82 (10.0) 4 (2.8) 19 (9.3) 4 (6.1)
Retired n (%) 212 (26.0) 29 (20.0) 52 (25.5) 23 (34.9) 0.02
Mother had COPD n (%) 98 (12.1) 13 (9.1) 26 (12.8) 3 (4.6) 0.21
Father had COPD n (%) 127 (16.0) 18 (13.1) 48 (23.9) 17 (26.2) 0.007
Occupational exposure to vapours,
gases, dusts and fumes n (%)
493 (61.6) 91 (63.2) 107 (52.7) 44 (66.7) 0.07
*P value w2-test; zt-test test; yyKruskal–Wallis test; IQR ¼ inter quartile range.
Reduced diffusing capacity and airflow obstruction 1733Notably, those with a reduced DLco only reported more
morning and chronic phlegm than those with only airflow
obstruction. Table 3 shows the symptoms that were
independently associated with airflow obstruction and/
or reduced diffusing capacity. None of the respiratory
symptoms were associated with low diffusing capacity
only. Wheeze was associated with airflow obstruction in
those with and without reduced diffusing capacity.
Morning cough and SOB Grade 2 were also significantly
associated with having both airflow obstruction and a
reduced DLco.Comparison of health care utilisation between
groups
Health care utilisation between the groups was also
compared (Fig. 2). We observed that airflow obstruction
was the main determinant of the usage of health services. In
subjects with airflow obstruction alone a significantly higher
proportion reported use of inhaled or oral medications.
However those subjects with both airflow obstruction and a
reduced diffusing capacity were more likely to have seen a
doctor, spent a night in hospital, visited a specialist and
undergone laboratory tests of some sort in the last 12months. The majority had chest X-rays or lung function tests
performed.Risk factors for reduced DLco in those with and
without airflow obstruction
Table 4 reports the odds ratios (OR) and 95% CIs for risk factors
found to be significantly associated with disease risk. Females
had a lesser risk of a reduced diffusing capacity in those with
and without airflow obstruction. Current smoking was signifi-
cantly associated with a reduced diffusing capacity alone and in
those with both a reduced diffusing capacity and airflow
obstruction. Pack years as a measure of smoking intensity was
also found to be an important risk factor for a reduced diffusing
capacity in combination with airflow obstruction. Having a
lower BMI was associated with a lesser risk of airflow
obstruction in those with and without a reduced diffusing
capacity. Bronchial hyperreactivity was found to be a risk factor
for both airflow obstruction alone and in combination with a
reduced diffusing capacity. Atopy was associated with a lesser
risk of the combination of airflow obstruction and a reduced
diffusing capacity. A serious respiratory tract infection before 5
years of age was significantly associated with the combination
of airflow obstruction and reduced diffusing capacity.
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Figure 1 Comparison of respiratory symptoms between disease groups. *Po0.001 for a comparison to the normal group.
Table 3 Respiratory symptoms associated with the three disease groups (Odds ratios and 95% confidence intervals).
Respiratory symptoms DLcooLLN only FEV1/FVCoLLN only Both
Wheeze 1.12 (0.70, 1.82) 2.12 (1.41, 3.21)yy 3.19 (1.67, 6.13)yy
Exertive SOB 1.42 (0.84, 2.40) 1.32 (0.82, 2.11) 1.35 (0.66, 2.79)
Morning cough 1.23 (0.63, 2.38) 1.44 (0.80, 2.59) 2.70 (1.20, 6.10)z
Chronic cough 0.81 (0.32, 2.07) 1.35 (0.65, 2.80) 0.99 (0.35, 2.80)
Morning sputum 2.13 (0.95, 4.79) 0.75 (0.30, 1.87) 1.95 (0.73, 5.23)
Chronic bronchitis 2.14 (0.54, 8.48) 0.98 (0.24, 3.94) 1.77 (0.40, 7.72)
SOB Grade 2 1.59 (0.85, 2.96) 1.42 (0.88, 2.31) 2.72 (1.27, 5.81)z
SOB Grade 3 4.10 (0.89, 18.9) 0.29 (0.03, 2.34) 2.35 (0.45, 12.4)
Age 0.97 (0.95, 1.00) 1.01 (0.99, 1.04) 1.04 (0.99, 1.08)
Sex (female) 0.03 (0.01, 0.07)yy 0.83 (0.57, 1.22) 0.07 (0.03, 0.18)yy
zP ¼ 0.02; yP ¼ 0.001; yyP ¼ 0.0001.
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Figure 2 Comparison of health care utilisation between disease groups. *Po0.001 for a comparison to the normal group.
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Table 4 Independent risk factors for the three disease groups (Odds ratios and 95% confidence intervals).
Risk factors DLcooLLN only FEV1/FVCoLLN only Both
Age 0.97 (0.94, 1.00) 1.00 (0.98, 1.03) 1.04 (0.99, 1.09)
Sex (female) 0.04 (0.01, 0.09)yy 0.66 (0.43, 1.01) 0.07 (0.03, 0.19)yy
Current smoking 4.38 (2.42, 7.93)yy 1.04 (0.54, 2.02) 3.88 (1.72, 8.74)y
Pack years 1.01 (0.99, 1.02) 1.01 (1.00, 1.02) 1.03 (1.01, 1.05)y
BMI 0.98 (0.93, 1.04) 0.95 (0.90, 0.99)z 0.84 (0.76, 0.93)y
Atopy 0.95 (0.60, 1.50) 0.75 (0.49, 1.14) 0.50 (0.24, 1.00)z
BHR 0.51 (0.20, 1.30) 6.67 (4.22, 10.5)yy 5.65 (2.63, 12.1)yy
Serious RTI 1.06 (0.59, 1.89) 1.28 (0.80, 2.05) 2.32 (1.14, 4.75)z
Mother COPD 0.87 (0.39, 1.95) 0.87 (0.45, 1.71) 0.45 (0.09, 2.13)
Father COPD 0.58 (0.28, 1.21) 1.06 (0.62, 1.81) 1.74 (0.77, 3.94)
Vapours, gases, dusts and fumes 1.04 (0.65, 1.66) 0.78 (0.52, 1.18) 1.21 (0.58, 2.51)
zP ¼ 0.02; yP ¼ 0.001; yyP ¼ 0.0001.
Reduced diffusing capacity and airflow obstruction 1735Discussion
The purpose of this analysis was to determine if measuring
DLco in combination with airflow obstruction would add
clinically relevant information to an epidemiological study
of the general population. Measurement of DLco proved
practical in this large scale epidemiological study. This is one
of the first studies to investigate factors that were
independently associated with a reduced DLco in individuals
with airflow obstruction in a randomly selected community
sample.
Tobacco smoking is the single most important risk factor
for COPD.25,26 In this population, 39% of individuals with
both reduced diffusing capacity and airflow obstruction
were current smokers and nearly 80% had ever been
smokers. Notably current smoking was significantly asso-
ciated with a reduced diffusing capacity in those with and
without airflow obstruction. Pack years of smoking was also
significantly associated with a reduced DLco with airflow
obstruction. These results are consistent with the well
known association between current cigarette smoking and
the parenchymal lung damage that results in emphysema
and reduced diffusing capacity.27,28 Longitudinal studies of
decline in DLco have not demonstrated significant differ-
ences in rate of decline between never, ever and current
smokers, but have demonstrated that current smokers have
lower mean levels of DLco.28–30 The results of our study are
consistent with the finding that only current smoking but not
ever smoking is associated with reduced DLco levels,
whether airflow obstruction is present or not.
BHR was found to be a significant risk factor for airflow
obstruction with or without a reduced DLco. The association
with BHR remained significant even when individuals with an
‘‘attack of asthma’’ in the last 12 months were removed
from the analysis. BHR is regarded as a cardinal feature of
asthma, but it is also observed in some subjects with
COPD.31 Whether BHR is a risk factor for the development of
COPD or develops because of airflow obstruction caused by
other factors has yet to be fully determined.32 We observed
a lesser risk of the development of airflow obstruction
combined with a reduced diffusing capacity among those
with atopy. They were less likely to be current or past
smokers. Previous studies have also found a decreased
current smoking prevalence with increasing degree of skinreactivity.33 This suggests that atopic individuals are less
likely to be regular smokers because of increased suscept-
ibility to bronchial irritants. There appears to be little
published information examining the relationship between
BHR and DLco or DLco/VA, in subjects with airflow
obstruction. The implication that BHR may predispose to
chronic airway disease fits into the ‘‘Dutch Hypothesis’’ of
COPD aetiology.34
A previous general population study found early childhood
respiratory infection to be a risk factor for airflow
obstruction.35 There is evidence to suggest that childhood
respiratory infections result in slower lung growth and lower
maximal attained pulmonary function in adulthood.36 It has
also been shown that pneumonia in early life can result in
permanent lung scarring and impaired lung growth.37 Viral
infections are capable of persisting after an acute infection
and it has been suggested that latent virus is capable of
amplifying cigarette smoke-induced lung damage.38 Our
data would support such conclusions as both serious child-
hood respiratory tract infection and cigarette smoking were
independent risk factors for a reduced DLco with airflow
obstruction.
Reduced diffusing capacity with airflow obstruction
identified a group of individuals with significant respiratory
morbidity. They reported more symptoms and had worse
lung function than subjects with airflow obstruction alone,
which supports the value of adding reduced DLco to the
definition of COPD. However we did not find much
difference between the two groups in health care utilisa-
tion, which is likely to reflect the low proportion of these
subjects with a doctor’s diagnosis of COPD.
We used the lower limit of normal as the cut-off to define
those with evidence of a reduced diffusing capacity or
airflow limitation. This is commonly used in the clinical
setting due to its statistical validity.39 The lower limit of
normal definition has statistical validity in that by definition
97.5% of the general healthy population will meet or exceed
this value and people falling below this level can be reliably
defined as having pulmonary disease.40
Some previous studies have suggested that full single
breath DLco manoeuvres can be successfully performed in
between 50% and 80% of subjects. A Norwegian study found
that all subjects were able to maintain a breath hold time
for between 9 and 11 s and 98% were able to provide
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good agreement was observed between duplicate man-
oeuvres for DLco and VA. Haemoglobin (Hb) measurement
was not available from 21 subjects due to failed or refused
venipuncture and in these subjects an uncorrected DLco
value was used. The intraclass (within subject) correlation
between the corrected and uncorrected DLco values was
very good (0.98), so it is unlikely that this has substantially
affected the results.
It is important that DLco measurements are corrected for
the presence of a significant CO back pressure and COHb
which are known to reduce DLco in heavy smokers.11 While we
did ask subjects not to smoke for 6 h before the test to reduce
this bias, we did not confirm compliance with this request. It
is therefore possible that DLco in our smokers was system-
atically underestimated, but it has been shown that this is
unlikely to fully account for the lower DLco in smokers.28
Furthermore, DLco remains a useful measure in epidemiolo-
gical studies even when CO back pressure is not measured.42
We did not ask female participants about their date of last
menses, so we could not correct for the affects of menstrual
cycle on DLco,43 but because of the age-group studied this is
unlikely to have any meaningful affect on the results.
Bronchodilator reversibility was not assessed in all
subjects with airflow limitation. A bronchodilator was only
administered where there was substantial airflow obstruc-
tion, which precluded methacholine challenge. The GOLD
definition of COPD specifies that all FEV1 values should be
post bronchodilator.2 This may have introduced some bias
into the assessment of airflow obstruction and may have
been a possible explanation for the associations with BHR if
we take this as a surrogate for asthma i.e. significant
bronchodilator response. It has been shown that the BHR and
the bronchodilator response are two different phenotypic
markers and are not interchangeable in epidemiological
studies.44 Without the assessment of reversibility it is
unclear whether potentially reversible airflow obstruction
influenced our results. We did exclude asthmatics from the
analysis, furthermore a high proportion of COPD patients
have ‘significant’ bronchodilator reversibility,45 so it is not
easy to differentiate COPD and asthma on this basis.
In conclusion, reduced DLco plus airflow obstruction
identifies a group of individuals with significantly more
symptoms, and worse lung function than subjects with
airflow obstruction alone. Current rather than former
cigarette smoking was found to be strongly associated with
a reduced DLco, highlighting the need to actively promote
smoking cessation even where airflow obstruction is not
evident. The prevention of serious respiratory infections
with the progressive and sustained introduction of pertussis,
measles and pneumococcal vaccines to early childhood
immunisation schedules may reduce the burden of COPD in
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